4.6 Article

Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma

期刊

NEURO-ONCOLOGY
卷 11, 期 6, 页码 842-852

出版社

OXFORD UNIV PRESS INC
DOI: 10.1215/15228517-2009-005

关键词

brain glioma; extent of resection; GBM; glioblastoma; MRI; tumor growth

资金

  1. National Cancer Institute [P50 CA97257, R01 CA59880]

向作者/读者索取更多资源

To assess Incidence and degree of regrowth in glioblastoma between surgery and radiation therapy (RT) and to correlate regrowth with presurgical imaging and survival, we examined images of 32 patients with newly diagnosed glioblastoma who underwent MR spectroscopic imaging (MRSI), perfusion-weighted imaging (PWI), and diffusion-weighted imaging (DWI) prior to surgery, after surgery, and prior to RT/temozolomide. Contrast enhancement (CE) in the pre-RT MR image was compared with postsurgical DWI to differentiate tumor growth from postsurgical infarct. MRSI and PWI parameters were analyzed prior to surgery and pre-RT. Postsurgical MRI indicated that 1.8 patients had gross total and 14 subtotal resections. Twenty-one patients showed reduced diffusion, and 25 patients showed new or increased CE. In eight patients (25%), the new CE was confined to areas of postsurgical reduced diffusion. In the other 17 patients (53%), new CE was found to be indicative of tumor growth or a combination of tumor growth and surgical injury. Higher perfusion and creatine within nonenhancing tumor in the presurgery MR were associated with subsequent tumor growth. High levels of choline and reduced diffusion in pre-RT CE suggested active metabolism and tumor cell prolifera-tion. Median survival was 1.4.6 months in patients with interim tumor growth and 24 months in patients with no growth. Increased volume or new onset of CE between surgery and RT was attributed to tumor growth in 53% of patients and was associated with shorter survival. This suggests that reducing the time between surgery and adjuvant therapy may be important. The acquisition of metabolic and physiologic imaging data prior to adjuvant therapy may also be valuable in assessing regions of new CE and nonenhancing tumor. Neuro-Oncology 11, 842852, 2009 (Posted to Neuro-Oncology [serial online], Doc. D08-00064, February 19, 2009. URL http://neuro-oncology.dukejournals.org; DOI: 10.1215/152285172009-005)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据